Additive growth inhibition after combined treatment of 2-methoxyestradiol and conventional chemotherapeutic agents in human pancreatic cancer cells

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4619-4624

  Fotopoulou, Christina ^a   Baumunk, Daniel ^a   Schmidt, Sven C ^a   Schumacher, Guido ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

2 methoxyestradiol; Apoptosis; Combination therapy; Gemcitabine; Pancreatic cancer cells

Indexed keywords

2 METHOXYESTRADIOL; CETUXIMAB; CISPLATIN; FLUOROURACIL; GEMCITABINE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CELL CYCLE ARREST; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT DURATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DEOXYCYTIDINE; DRUG SYNERGISM; ESTRADIOL; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FLUOROURACIL; HUMANS; MICE; MICE, NUDE; PACLITAXEL; PANCREATIC NEOPLASMS; TUBULIN MODULATORS;

EID: 78650246609     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Oettle H, Post S, Neuhaus P, Geliert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B and Riess H: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama 297: 267-277, 2007.
2. Endlicher E, Troppmann M, Kullmann A, Golder S, Herold T, Herfarth H, Grossmann J, Schlottmann K and Kullmann F: Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study. Oncology 72: 279-284, 2008.
3. 125I- labelled ligand. Acta Endocrinol (Copenh) 103: 282-288, 1983.
4. D'Amato RJ, Lin CM, Flynn E, Folkman J and Hamel E: 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 91: 3964-3968, 1994.
5. Amin AM, Creveling CR and Lowe MC: Immunohistochemical localization of catechol methyltransferase in normal and cancerous breast tissues of mice and rats. J Natl Cancer Inst 70: 337-342, 1983.
6. Merriam GR, MacLusky NJ, Picard MK and Naftolin F: Comparative properties of the catechol estrogens, I: methylation by catechol-O-methyltransferase and binding to cytosol estrogen receptors. Steroids 36: 1-11, 1980.
7. La Vallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ and Pribluda VS: 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res 62: 3691-3697, 2002.
8. Schumacher G and Neuhaus P: The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol 127: 405-410, 2001.
9. Schumacher G and Neuhaus P: 2-Methoxyestradiol - a new compound for cancer treatment. Dtsch Med Wochenschr 131: 825-830, 2006.
10. Schumacher G, Kataoka M, Roth JA and Mukhopadhyay T: Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 5: 493-499, 1999.
11. Schumacher G, Hoffmann J, Cramer T, Spinelli A, Jacob D, Bahra M, Pratschke J, Pfitzmann R, Schmidt S and Lage H: Antineoplastic activity of 2-methoxyestradiol in human pancreatic and gastric cancer cells with different multidrug-resistant phenotypes. J Gastroenterol Hepatol 22: 1469-1473, 2007.
12. Weber AK, Wahn U and Renz H: Superantigen-induced T cell death by apoptosis: analysis on a single cell level and effect of IFN-gamma and IL-4 treatment. Int Arch Allergy Immunol 121: 215-223, 2000.
13. Hurt EM, Thomas SB, Peng B and Farrar WL: Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines. Br J Cancer 97: 1116-1123, 2007.
14. Basu A, Castle VP, Bouziane M, Bhalla K and Haldar S: Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family. Cancer Res 66: 4309-4318, 2006.
15. Ryschich E, Werner J, Gebhard MM, Klar E and Schmidt J: Asngiogenesis inhibition with TNP-470, 2-methoxyestradiol, and paclitaxel in experimental pancreatic carcinoma. Pancreas 26: 166-172, 2003.
16. Qanungo S, Basu A, Das M and Haldar S: 2-Methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells. Oncogene 21: 4149-4157, 2002.
17. Nair SK, Verma A, Thomas T J, Chou TC, Gallo MA, Shirahata A and Thomas T: Synergistic apoptosis of MCF-7 breast cancer cells by 2-methoxyestradiol and bis(ethyl)norspermine. Cancer Lett 250: 311-322, 2007.
18. Clark EA, Hills PM, Davidson BS, Wender PA and Mooberry SL: Laulimalide and synthetic laulimalide analogues are synergistic with paclitaxel and 2-methoxyestradiol. Mol Pharm 3: 457-467, 2006.
19. Sato F, Fukuhara H and Basilion JP: Effects of hormone deprivation and 2-methoxyestradiol combination therapy on hormone-dependent prostate cancer in vivo. Neoplasia 7: 838-846, 2005.
20. Han GZ, Liu ZJ, Shimoi K and Zhu BT: Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res 65: 387-393, 2005.
21. Ricker JL, Chen Z, Yang XP, Pribluda VS, Swartz GM and Van Waes C: 2-Methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 10: 8665-8673, 2004.
22. Mueck AO, Seeger H, Wallwiener D and Huober J: Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations. Eur J Gynaecol Oncol 25: 699-701, 2004.
23. Sweeney CJ, Miller K D, Sissons SE, Nozaki S, Heilman DK, Shen J and Sledge GW Jr.: The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61: 3369-3372, 2001.
24. Kataoka M, Schumacher G, Cristiano R J, Atkinson E N, Roth J A and Mukhopadhyay T: An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo. Cancer Res 58: 4761-4765, 1998.
25. James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C and Miller KD: Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 25: 41-48, 2007.
26. Gonzalez VM, Fuertes MA, Alonso C and Perez J M: Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59: 657-663, 2001.
27. Lee SH, Ryu JK, Lee KY, Woo SM, Park JK, Yoo JW, Kim YT and Yoon YB: Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett 259: 39-49, 2008.
28. Adamsen BL, Kravik KL, Clausen OP and De Angelis PM: Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol 31: 1491-1500, 2007.
29. Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN and Myers JN: Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 12: 600-607, 2006. (Pubitemid 43166155)
30. Fotsis T, Zhang Y, Pepper M S, Adlercreutz H, Montesano R, Nawroth PP and Schweigerer L: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368: 237-239, 1994.
31. Klauber N, Parangi S, Flynn E, Hamel E and D'Amato RJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57: 81-86, 1997.